Department of Pharmacy, Guangdong Province Hospital of Integrated Traditional Chinese and Western Medicine, Foshan, 528200, China.
Departments of Human Biology (Neuroscience), University of Toronto, Toronto, M5S 1A1, Canada.
J Neural Transm (Vienna). 2018 Dec;125(12):1781-1786. doi: 10.1007/s00702-018-1936-7. Epub 2018 Oct 3.
The -2518A/G polymorphism in monocyte chemotactic protein-1 (MCP-1) has been extensively investigated for association with Alzheimer's disease (AD); however, the results from different studies are inconsistent. The aim of this study was to draw an accurate conclusion of the association. All eligible case-control studies were searched in PubMed, Embase, Chinese National Knowledge Infrastructure, China Biological Medicine Databases, and Wanfang Databases. Eight case-control studies with a total of 2370 cases and 2413 controls were eligible to be included in this meta-analysis. The association was evaluated by calculating the odds ratios (ORs) with the corresponding 95% confidence intervals (CIs). Overall, there was no significant association between MCP-1-2518A/G polymorphism and AD risk in all genetic models (the allele model G vs. A: OR = 1.15, 95% CI 0.92-1.45, p = 0.22; the co-dominant model GG vs. AA: OR = 1.38, 95% CI 0.80-2.36, p = 0.25; the dominant model AG + GG vs. AA: OR = 1.14, 95% CI 0.89-1.46, p = 0.31; the recessive model GG vs. AG + AA: OR = 1.35, 95% CI 0.87-2.09, p = 0.18). In subgroup analysis by ethnicity, a significant difference was not detected in both Caucasians and Asians. In allele model (G vs. A), the required sample size of 31858 was calculated by applying trial sequential analysis. Cumulative z curve is always below the trial sequential monitoring boundary and is nominally statistically significant (Z = 1.96). A consistent result was obtained in other genetic models. In summary, the present meta-analysis suggests that MCP-1-2518A/G polymorphism may not be associated with genetic susceptibility of AD in general population, but the association remains indeterminate due to the insufficient evidence.
单核细胞趋化蛋白-1（MCP-1）-2518A/G 多态性已被广泛研究与阿尔茨海默病（AD）相关；然而，不同研究的结果并不一致。本研究旨在得出准确的相关性结论。我们在 PubMed、Embase、中国知网、中国生物医学文献数据库和万方数据库中搜索了所有符合条件的病例对照研究。共有 8 项病例对照研究，共 2370 例病例和 2413 例对照符合纳入本 meta 分析的标准。我们通过计算相应的 95%置信区间（CI）来评估优势比（ORs）。总的来说，在所有遗传模型中，MCP-1-2518A/G 多态性与 AD 风险之间没有显著关联（等位基因模型 G 对 A：OR=1.15，95%CI 0.92-1.45，p=0.22；共显性模型 GG 对 AA：OR=1.38，95%CI 0.80-2.36，p=0.25；显性模型 AG+GG 对 AA：OR=1.14，95%CI 0.89-1.46，p=0.31；隐性模型 GG 对 AG+AA：OR=1.35，95%CI 0.87-2.09，p=0.18）。按种族亚组分析，在白人和亚洲人中均未检测到显著差异。在等位基因模型（G 对 A）中，应用试验序贯分析计算出需要 31858 个样本量。累积 z 曲线始终低于试验序贯监测边界，名义上具有统计学意义（Z=1.96）。其他遗传模型也得到了一致的结果。总之，本 meta 分析表明，MCP-1-2518A/G 多态性与一般人群 AD 的遗传易感性可能无关，但由于证据不足，其相关性仍不确定。
